Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Aug;85(4):473–483. doi: 10.1054/bjoc.2001.1943

Chronic immune activation and inflammation as the cause of malignancy

K J O'Byrne 1, A G Dalgleish 2
PMCID: PMC2364095  PMID: 11506482

Abstract

Several chronic infections known to be associated with malignancy have established oncogenic properties. However the existence of chronic inflammatory conditions that do not have an established infective cause and are associated with the development of tumours strongly suggests that the inflammatory process itself provides the prerequisite environment for the development of malignancy. This environment includes upregulation of mediators of the inflammatory response such as cyclo-oxygenase (COX)-2 leading to the production of inflammatory cytokines and prostaglandins which themselves may suppress cell mediated immune responses and promote angiogenesis. These factors may also impact on cell growth and survival signalling pathways resulting in induction of cell proliferation and inhibition of apoptosis. Furthermore, chronic inflammation may lead to the production of reactive oxygen species and metabolites such as malondialdehyde within the affected cells that may in turn induce DNA damage and mutations and, as a result, be carcinogenic. Here it is proposed that the conditions provided by a chronic inflammatory environment are so essential for the progression of the neoplastic process that therapeutic intervention aimed at inhibiting inflammation, reducing angiogenesis and stimulating cell mediated immune responses may have a major role in reducing the incidence of common cancers. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: cell mediated immunity, humoral immunity, angiogenesis, cancer

Full Text

The Full Text of this article is available as a PDF (156.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akre K., Ekström A. M., Signorello L. B., Hansson L. E., Nyrén O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer. 2001 Apr 6;84(7):965–968. doi: 10.1054/bjoc.2001.1702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Athar M., An K. P., Morel K. D., Kim A. L., Aszterbaum M., Longley J., Epstein E. H., Jr, Bickers D. R. Ultraviolet B(UVB)-induced cox-2 expression in murine skin: an immunohistochemical study. Biochem Biophys Res Commun. 2001 Feb 2;280(4):1042–1047. doi: 10.1006/bbrc.2000.4201. [DOI] [PubMed] [Google Scholar]
  3. Badawi A. F., Mostafa M. H., Probert A., O'Connor P. J. Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis. Eur J Cancer Prev. 1995 Feb;4(1):45–59. doi: 10.1097/00008469-199502000-00004. [DOI] [PubMed] [Google Scholar]
  4. Bergers G., Javaherian K., Lo K. M., Folkman J., Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999 Apr 30;284(5415):808–812. doi: 10.1126/science.284.5415.808. [DOI] [PubMed] [Google Scholar]
  5. Bielefeldt-Ohmann H., Jarnicki A. G., Fitzpatrick D. R. Molecular pathobiology and immunology of malignant mesothelioma. J Pathol. 1996 Apr;178(4):369–378. doi: 10.1002/(SICI)1096-9896(199604)178:4<369::AID-PATH460>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  6. Bonnet M., Guinebretiere J. M., Kremmer E., Grunewald V., Benhamou E., Contesso G., Joab I. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst. 1999 Aug 18;91(16):1376–1381. doi: 10.1093/jnci/91.16.1376. [DOI] [PubMed] [Google Scholar]
  7. Bontkes H. J., de Gruijl T. D., Bijl A., Verheijen R. H., Meijer C. J., Scheper R. J., Stern P. L., Burns J. E., Maitland N. J., Walboomers J. M. Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia. J Gen Virol. 1999 Sep;80(Pt 9):2453–2459. doi: 10.1099/0022-1317-80-9-2453. [DOI] [PubMed] [Google Scholar]
  8. Bontkes H. J., de Gruijl T. D., Walboomers J. M., Schiller J. T., Dillner J., Helmerhorst T. J., Verheijen R. H., Scheper R. J., Meijer C. J. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol. 1999 Feb;80(Pt 2):409–417. doi: 10.1099/0022-1317-80-2-409. [DOI] [PubMed] [Google Scholar]
  9. Béraud C., Henzel W. J., Baeuerle P. A. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):429–434. doi: 10.1073/pnas.96.2.429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Carbone M., Rizzo P., Grimley P. M., Procopio A., Mew D. J., Shridhar V., de Bartolomeis A., Esposito V., Giuliano M. T., Steinberg S. M. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med. 1997 Aug;3(8):908–912. doi: 10.1038/nm0897-908. [DOI] [PubMed] [Google Scholar]
  11. Cardone M. H., Roy N., Stennicke H. R., Salvesen G. S., Franke T. F., Stanbridge E., Frisch S., Reed J. C. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998 Nov 13;282(5392):1318–1321. doi: 10.1126/science.282.5392.1318. [DOI] [PubMed] [Google Scholar]
  12. Castelao J. E., Yuan J. M., Gago-Dominguez M., Yu M. C., Ross R. K. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer. 2000 Apr;82(7):1364–1369. doi: 10.1054/bjoc.1999.1106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cerqueira E. M., Santoro C. L., Donozo N. F., Freitas B. A., Pereira C. A., Bevilacqua R. G., Machado-Santelli G. M. Genetic damage in exfoliated cells of the uterine cervix. Association and interaction between cigarette smoking and progression to malignant transformation? Acta Cytol. 1998 May-Jun;42(3):639–649. doi: 10.1159/000331820. [DOI] [PubMed] [Google Scholar]
  14. Clavel C., Masure M., Levert M., Putaud I., Mangeonjean C., Lorenzato M., Nazeyrollas P., Gabriel R., Quereux C., Birembaut P. Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions. Diagn Mol Pathol. 2000 Sep;9(3):145–150. doi: 10.1097/00019606-200009000-00004. [DOI] [PubMed] [Google Scholar]
  15. Clerici M., Shearer G. M. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today. 1994 Dec;15(12):575–581. doi: 10.1016/0167-5699(94)90220-8. [DOI] [PubMed] [Google Scholar]
  16. Coffey D. S. Self-organization, complexity and chaos: the new biology for medicine. Nat Med. 1998 Aug;4(8):882–885. doi: 10.1038/nm0898-882. [DOI] [PubMed] [Google Scholar]
  17. Cordon-Cardo C., Prives C. At the crossroads of inflammation and tumorigenesis. J Exp Med. 1999 Nov 15;190(10):1367–1370. doi: 10.1084/jem.190.10.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Cox G., Jones J. L., O'Byrne K. J. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res. 2000 Jun;6(6):2349–2355. [PubMed] [Google Scholar]
  19. Dalgleish A. G. The pathogenesis of AIDS: classical and alternative views. J R Coll Physicians Lond. 1992 Apr;26(2):152–158. [PMC free article] [PubMed] [Google Scholar]
  20. Dalgleish A. G. Viruses and cancer. Br Med Bull. 1991 Jan;47(1):21–46. doi: 10.1093/oxfordjournals.bmb.a072457. [DOI] [PubMed] [Google Scholar]
  21. Dalgleish A. The relevance of non-linear mathematics (chaos theory) to the treatment of cancer, the role of the immune response and the potential for vaccines. QJM. 1999 Jun;92(6):347–359. doi: 10.1093/qjmed/92.6.347. [DOI] [PubMed] [Google Scholar]
  22. Dameron K. M., Volpert O. V., Tainsky M. A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994 Sep 9;265(5178):1582–1584. doi: 10.1126/science.7521539. [DOI] [PubMed] [Google Scholar]
  23. De Luca A., Baldi A., Esposito V., Howard C. M., Bagella L., Rizzo P., Caputi M., Pass H. I., Giordano G. G., Baldi F. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas. Nat Med. 1997 Aug;3(8):913–916. doi: 10.1038/nm0897-913. [DOI] [PubMed] [Google Scholar]
  24. De Marzo A. M., Coffey D. S., Nelson W. G. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology. 1999 Mar;53(3 Suppl 3A):29–42. doi: 10.1016/s0090-4295(98)00536-6. [DOI] [PubMed] [Google Scholar]
  25. Della Bella S., Molteni M., Compasso S., Zulian C., Vanoli M., Scorza R. Differential effects of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes. Prostaglandins Leukot Essent Fatty Acids. 1997 Mar;56(3):177–184. doi: 10.1016/s0952-3278(97)90531-7. [DOI] [PubMed] [Google Scholar]
  26. Di Popolo A., Memoli A., Apicella A., Tuccillo C., di Palma A., Ricchi P., Acquaviva A. M., Zarrilli R. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells. Oncogene. 2000 Nov 16;19(48):5517–5524. doi: 10.1038/sj.onc.1203952. [DOI] [PubMed] [Google Scholar]
  27. Doherty P. C., Tripp R. A., Sixbey J. W. Evasion of host immune responses by tumours and viruses. Ciba Found Symp. 1994;187:245–260. doi: 10.1002/9780470514672.ch16. [DOI] [PubMed] [Google Scholar]
  28. Dubois R. N., Abramson S. B., Crofford L., Gupta R. A., Simon L. S., Van De Putte L. B., Lipsky P. E. Cyclooxygenase in biology and disease. FASEB J. 1998 Sep;12(12):1063–1073. [PubMed] [Google Scholar]
  29. Dumas F., Eschwège P., Loric S. Acute bacterial prostatitis induces hematogenous dissemination of prostate epithelial cells. Clin Chem. 1997 Oct;43(10):2007–2008. [PubMed] [Google Scholar]
  30. Duperron C., Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis. 1997 May;18(5):1001–1006. doi: 10.1093/carcin/18.5.1001. [DOI] [PubMed] [Google Scholar]
  31. Edwards J. G., Abrams K. R., Leverment J. N., Spyt T. J., Waller D. A., O'Byrne K. J. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax. 2000 Sep;55(9):731–735. doi: 10.1136/thorax.55.9.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. El-Bayoumy K., Iatropoulos M., Amin S., Hoffmann D., Wynder E. L. Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone: the impact of a high-fat diet. Cancer Res. 1999 Apr 1;59(7):1400–1403. [PubMed] [Google Scholar]
  33. Eliopoulos A. G., Gallagher N. J., Blake S. M., Dawson C. W., Young L. S. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem. 1999 Jun 4;274(23):16085–16096. doi: 10.1074/jbc.274.23.16085. [DOI] [PubMed] [Google Scholar]
  34. Faux S. P., Houghton C. E., Hubbard A., Patrick G. Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres. Carcinogenesis. 2000 Dec;21(12):2275–2280. doi: 10.1093/carcin/21.12.2275. [DOI] [PubMed] [Google Scholar]
  35. Faux S. P., Howden P. J. Possible role of lipid peroxidation in the induction of NF-kappa B and AP-1 in RFL-6 cells by crocidolite asbestos: evidence following protection by vitamin E. Environ Health Perspect. 1997 Sep;105 (Suppl 5):1127–1130. doi: 10.1289/ehp.97105s51127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Fleming S. Renal cancer genetics: von Hippel Lindau and other syndromes. Int J Dev Biol. 1999;43(5):469–471. [PubMed] [Google Scholar]
  37. Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995 Dec 28;333(26):1757–1763. doi: 10.1056/NEJM199512283332608. [DOI] [PubMed] [Google Scholar]
  38. Funkhouser E. M., Sharp G. B. Aspirin and reduced risk of esophageal carcinoma. Cancer. 1995 Oct 1;76(7):1116–1119. doi: 10.1002/1097-0142(19951001)76:7<1116::aid-cncr2820760703>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  39. Gabrilovich D. I., Ishida T., Nadaf S., Ohm J. E., Carbone D. P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999 Oct;5(10):2963–2970. [PubMed] [Google Scholar]
  40. Gallucci R. M., Simeonova P. P., Matheson J. M., Kommineni C., Guriel J. L., Sugawara T., Luster M. I. Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J. 2000 Dec;14(15):2525–2531. doi: 10.1096/fj.00-0073com. [DOI] [PubMed] [Google Scholar]
  41. Ganss R., Hanahan D. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 1998 Oct 15;58(20):4673–4681. [PubMed] [Google Scholar]
  42. Garrido F., Cabrera T., Concha A., Glew S., Ruiz-Cabello F., Stern P. L. Natural history of HLA expression during tumour development. Immunol Today. 1993 Oct;14(10):491–499. doi: 10.1016/0167-5699(93)90264-L. [DOI] [PubMed] [Google Scholar]
  43. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev. 2000;19(1-2):19–27. doi: 10.1023/a:1026575610124. [DOI] [PubMed] [Google Scholar]
  44. Giovannucci E., Egan K. M., Hunter D. J., Stampfer M. J., Colditz G. A., Willett W. C., Speizer F. E. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995 Sep 7;333(10):609–614. doi: 10.1056/NEJM199509073331001. [DOI] [PubMed] [Google Scholar]
  45. Giovannucci E., Rimm E. B., Stampfer M. J., Colditz G. A., Ascherio A., Willett W. C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994 Aug 15;121(4):241–246. doi: 10.7326/0003-4819-121-4-199408150-00001. [DOI] [PubMed] [Google Scholar]
  46. Gjertsen M. K., Bjorheim J., Saeterdal I., Myklebust J., Gaudernack G. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int J Cancer. 1997 Sep 4;72(5):784–790. doi: 10.1002/(sici)1097-0215(19970904)72:5<784::aid-ijc14>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  47. Gorter A., Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today. 1999 Dec;20(12):576–582. doi: 10.1016/s0167-5699(99)01537-6. [DOI] [PubMed] [Google Scholar]
  48. Grinwich K. D., Plescia O. J. Tumor-mediated immunosuppression: prevention by inhibitors of prostaglandin synthesis. Prostaglandins. 1977;14(6):1175–1182. doi: 10.1016/0090-6980(77)90294-5. [DOI] [PubMed] [Google Scholar]
  49. Guillou L., Estreicher A., Chaubert P., Hurlimann J., Kurt A. M., Metthez G., Iggo R., Gray A. C., Jichlinski P., Leisinger H. J. Germ cell tumors of the testis overexpress wild-type p53. Am J Pathol. 1996 Oct;149(4):1221–1228. [PMC free article] [PubMed] [Google Scholar]
  50. Habeshaw J., Hounsell E., Dalgleish A. Does the HIV envelope induce a chronic graft-versus-host-like disease? Immunol Today. 1992 Jun;13(6):207–210. doi: 10.1016/0167-5699(92)90155-Z. [DOI] [PubMed] [Google Scholar]
  51. Heriot A. G., Marriott J. B., Cookson S., Kumar D., Dalgleish A. G. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer. 2000 Mar;82(5):1009–1012. doi: 10.1054/bjoc.1999.1034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Hida T., Leyton J., Makheja A. N., Ben-Av P., Hla T., Martinez A., Mulshine J., Malkani S., Chung P., Moody T. W. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res. 1998 Mar-Apr;18(2A):775–782. [PubMed] [Google Scholar]
  53. Higaki S., Akazawa A., Nakamura H., Yanai H., Yoshida T., Okita K. Metaplastic polyp of the colon develops in response to inflammation. J Gastroenterol Hepatol. 1999 Jul;14(7):709–714. doi: 10.1046/j.1440-1746.1999.01938.x. [DOI] [PubMed] [Google Scholar]
  54. Hildesheim A., Schiffman M. H., Tsukui T., Swanson C. A., Lucci J., 3rd, Scott D. R., Glass A. G., Rush B. B., Lorincz A. T., Corrigan A. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease. Cancer Epidemiol Biomarkers Prev. 1997 Oct;6(10):807–813. [PubMed] [Google Scholar]
  55. Horikawa T., Yoshizaki T., Sheen T. S., Lee S. Y., Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer. 2000 Aug 15;89(4):715–723. doi: 10.1002/1097-0142(20000815)89:4<715::aid-cncr1>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  56. Hsieh C. Y., You S. L., Kao C. L., Chen C. J. Reproductive and infectious risk factors for invasive cervical cancer in Taiwan. Anticancer Res. 1999 Sep-Oct;19(5C):4495–4500. [PubMed] [Google Scholar]
  57. Hu P., Margolis B., Skolnik E. Y., Lammers R., Ullrich A., Schlessinger J. Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol Cell Biol. 1992 Mar;12(3):981–990. doi: 10.1128/mcb.12.3.981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Huang M., Stolina M., Sharma S., Mao J. T., Zhu L., Miller P. W., Wollman J., Herschman H., Dubinett S. M. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 1998 Mar 15;58(6):1208–1216. [PubMed] [Google Scholar]
  59. Huang Y. T., Sheen T. S., Chen C. L., Lu J., Chang Y., Chen J. Y., Tsai C. H. Profile of cytokine expression in nasopharyngeal carcinomas: a distinct expression of interleukin 1 in tumor and CD4+ T cells. Cancer Res. 1999 Apr 1;59(7):1599–1605. [PubMed] [Google Scholar]
  60. Hudson J. D., Shoaibi M. A., Maestro R., Carnero A., Hannon G. J., Beach D. H. A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999 Nov 15;190(10):1375–1382. doi: 10.1084/jem.190.10.1375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Höpfl R., Heim K., Christensen N., Zumbach K., Wieland U., Volgger B., Widschwendter A., Haimbuchner S., Müller-Holzner E., Pawlita M. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet. 2000 Dec 9;356(9246):1985–1986. doi: 10.1016/S0140-6736(00)03315-8. [DOI] [PubMed] [Google Scholar]
  62. Irani J., Goujon J. M., Ragni E., Peyrat L., Hubert J., Saint F., Mottet N. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathologist Multi Center Study Group. Urology. 1999 Sep;54(3):467–472. doi: 10.1016/s0090-4295(99)00152-1. [DOI] [PubMed] [Google Scholar]
  63. Jacobs N., Giannini S. L., Doyen J., Baptista A., Moutschen M., Boniver J., Delvenne P. Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix. Clin Exp Immunol. 1998 Jan;111(1):219–224. doi: 10.1046/j.1365-2249.1998.00437.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Jankowski J. A., Wright N. A., Meltzer S. J., Triadafilopoulos G., Geboes K., Casson A. G., Kerr D., Young L. S. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol. 1999 Apr;154(4):965–973. doi: 10.1016/S0002-9440(10)65346-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Janssen Y. M., Driscoll K. E., Howard B., Quinlan T. R., Treadwell M., Barchowsky A., Mossman B. T. Asbestos causes translocation of p65 protein and increases NF-kappa B DNA binding activity in rat lung epithelial and pleural mesothelial cells. Am J Pathol. 1997 Aug;151(2):389–401. [PMC free article] [PubMed] [Google Scholar]
  66. Jung K., Meyer A., Lein M., Rudolph B., Schnorr D., Loening S. A. Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. J Urol. 1998 May;159(5):1595–1598. doi: 10.1097/00005392-199805000-00050. [DOI] [PubMed] [Google Scholar]
  67. Kano A., Watanabe Y., Takeda N., Aizawa S., Akaike T. Analysis of IFN-gamma-induced cell cycle arrest and cell death in hepatocytes. J Biochem. 1997 Apr;121(4):677–683. doi: 10.1093/oxfordjournals.jbchem.a021639. [DOI] [PubMed] [Google Scholar]
  68. Keay S., Zhang C. O., Baldwin B. R., Alexander R. B. Polymerase chain reaction amplification of bacterial 16s rRNA genes in prostate biopsies from men without chronic prostatitis. Urology. 1999 Mar;53(3):487–491. doi: 10.1016/s0090-4295(98)00553-6. [DOI] [PubMed] [Google Scholar]
  69. Kirk G. R., Clements W. D. Crohn's disease and colorectal malignancy. Int J Clin Pract. 1999 Jun;53(4):314–315. [PubMed] [Google Scholar]
  70. Kitagawa N., Goto M., Kurozumi K., Maruo S., Fukayama M., Naoe T., Yasukawa M., Hino K., Suzuki T., Todo S. Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO J. 2000 Dec 15;19(24):6742–6750. doi: 10.1093/emboj/19.24.6742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Kodelja V., Müller C., Tenorio S., Schebesch C., Orfanos C. E., Goerdt S. Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology. 1997 Nov;197(5):478–493. doi: 10.1016/S0171-2985(97)80080-0. [DOI] [PubMed] [Google Scholar]
  72. Konturek P. C., Hartwich A., Zuchowicz M., Labza H., Pierzchalski P., Karczewska E., Bielanski W., Hahn E. G., Konturek S. J. Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer. J Physiol Pharmacol. 2000 Dec;51(4 Pt 1):737–749. [PubMed] [Google Scholar]
  73. Koshiba T., Hosotani R., Miyamoto Y., Wada M., Lee J. U., Fujimoto K., Tsuji S., Nakajima S., Doi R., Imamura M. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol. 1999 Oct;26(2):69–76. doi: 10.1007/BF02781733. [DOI] [PubMed] [Google Scholar]
  74. Lala P. K., Al-Mutter N., Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer. 1997 Nov 4;73(3):371–380. doi: 10.1002/(sici)1097-0215(19971104)73:3<371::aid-ijc12>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  75. Langman M. J., Cheng K. K., Gilman E. A., Lancashire R. J. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000 Jun 17;320(7250):1642–1646. doi: 10.1136/bmj.320.7250.1642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Le Buanec H., D'Anna R., Lachgar A., Zagury J. F., Bernard J., Ittelé D., d'Alessio P., Hallez S., Giannouli C., Burny A. HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes. Biomed Pharmacother. 1999 Oct;53(9):424–431. doi: 10.1016/S0753-3322(99)80122-X. [DOI] [PubMed] [Google Scholar]
  77. Lee P. P., Zeng D., McCaulay A. E., Chen Y. F., Geiler C., Umetsu D. T., Chao N. J. T helper 2-dominant antilymphoma immune response is associated with fatal outcome. Blood. 1997 Aug 15;90(4):1611–1617. [PubMed] [Google Scholar]
  78. Lengauer C., Kinzler K. W., Vogelstein B. Genetic instabilities in human cancers. Nature. 1998 Dec 17;396(6712):643–649. doi: 10.1038/25292. [DOI] [PubMed] [Google Scholar]
  79. Lewis J. D., Deren J. J., Lichtenstein G. R. Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 1999 Jun;28(2):459-77, x. doi: 10.1016/s0889-8553(05)70065-0. [DOI] [PubMed] [Google Scholar]
  80. Liu M. Y., Shih Y. Y., Li L. Y., Chou S. P., Sheen T. S., Chen C. L., Yang C. S., Chen J. Y. Expression of the Epstein-Barr virus BHRF1 gene, a homologue of Bcl-2, in nasopharyngeal carcinoma tissue. J Med Virol. 2000 Jun;61(2):241–250. doi: 10.1002/(sici)1096-9071(200006)61:2<241::aid-jmv11>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  81. Majima M., Isono M., Ikeda Y., Hayashi I., Hatanaka K., Harada Y., Katsumata O., Yamashina S., Katori M., Yamamoto S. Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn J Pharmacol. 1997 Oct;75(2):105–114. doi: 10.1254/jjp.75.105. [DOI] [PubMed] [Google Scholar]
  82. Maraveyas A., Baban B., Kennard D., Rook G. A., Westby M., Grange J. M., Lydyard P., Stanford J. L., Jones M., Selby P. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol. 1999 Jul;10(7):817–824. doi: 10.1023/a:1008307821189. [DOI] [PubMed] [Google Scholar]
  83. Mauray S., Fuzzati-Armentero M. T., Trouillet P., Rüegg M., Nicoloso G., Hart M., Aarden L., Schapira M., Duchosal M. A. Epstein-Barr virus-dependent lymphoproliferative disease: critical role of IL-6. Eur J Immunol. 2000 Jul;30(7):2065–2073. doi: 10.1002/1521-4141(200007)30:7<2065::AID-IMMU2065>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  84. Mayne S. T., Buenconsejo J., Janerich D. T. Previous lung disease and risk of lung cancer among men and women nonsmokers. Am J Epidemiol. 1999 Jan 1;149(1):13–20. doi: 10.1093/oxfordjournals.aje.a009722. [DOI] [PubMed] [Google Scholar]
  85. McCann J. Esophageal cancers: changing character, increasing incidence. J Natl Cancer Inst. 1999 Mar 17;91(6):497–498. doi: 10.1093/jnci/91.6.497. [DOI] [PubMed] [Google Scholar]
  86. McGinty A., Chang Y. W., Sorokin A., Bokemeyer D., Dunn M. J. Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells. J Biol Chem. 2000 Apr 21;275(16):12095–12101. doi: 10.1074/jbc.275.16.12095. [DOI] [PubMed] [Google Scholar]
  87. Melief C. J., Kast W. M. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms. Semin Cancer Biol. 1991 Oct;2(5):347–354. [PubMed] [Google Scholar]
  88. Mestre J. R., Chan G., Zhang F., Yang E. K., Sacks P. G., Boyle J. O., Shah J. P., Edelstein D., Subbaramaiah K., Dannenberg A. J. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann N Y Acad Sci. 1999;889:62–71. doi: 10.1111/j.1749-6632.1999.tb08724.x. [DOI] [PubMed] [Google Scholar]
  89. Molina M. A., Sitja-Arnau M., Lemoine M. G., Frazier M. L., Sinicrope F. A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999 Sep 1;59(17):4356–4362. [PubMed] [Google Scholar]
  90. Monson R. R., Yen S., MacMahon B. Chronic mastitis and carcinoma of the breast. Lancet. 1976 Jul 31;2(7979):224–226. doi: 10.1016/s0140-6736(76)91026-6. [DOI] [PubMed] [Google Scholar]
  91. Moore R. J., Owens D. M., Stamp G., Arnott C., Burke F., East N., Holdsworth H., Turner L., Rollins B., Pasparakis M. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 1999 Jul;5(7):828–831. doi: 10.1038/10552. [DOI] [PubMed] [Google Scholar]
  92. Mosmann T. R., Coffman R. L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–173. doi: 10.1146/annurev.iy.07.040189.001045. [DOI] [PubMed] [Google Scholar]
  93. Murata H., Kawano S., Tsuji S., Tsuji M., Sawaoka H., Kimura Y., Shiozaki H., Hori M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol. 1999 Feb;94(2):451–455. doi: 10.1111/j.1572-0241.1999.876_e.x. [DOI] [PubMed] [Google Scholar]
  94. Nakata S., Imai K., Yamanaka H. [Study of risk factors for prostatic cancer]. Hinyokika Kiyo. 1993 Nov;39(11):1017–1025. [PubMed] [Google Scholar]
  95. O'Byrne K. J., Dalgleish A. G., Browning M. J., Steward W. P., Harris A. L. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer. 2000 Jan;36(2):151–169. doi: 10.1016/s0959-8049(99)00241-5. [DOI] [PubMed] [Google Scholar]
  96. Paganini-Hill A. Aspirin and the prevention of colorectal cancer: a review of the evidence. Semin Surg Oncol. 1994 May-Jun;10(3):158–164. doi: 10.1002/ssu.2980100303. [DOI] [PubMed] [Google Scholar]
  97. Pamphilon D. H., Alnaqdy A. A., Wallington T. B. Immunomodulation by ultraviolet light: clinical studies and biological effects. Immunol Today. 1991 Apr;12(4):119–123. doi: 10.1016/0167-5699(91)90095-B. [DOI] [PubMed] [Google Scholar]
  98. Pettit S. J., Seymour K., O'Flaherty E., Kirby J. A. Immune selection in neoplasia: towards a microevolutionary model of cancer development. Br J Cancer. 2000 Jun;82(12):1900–1906. doi: 10.1054/bjoc.2000.1206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Peus D., Vasa R. A., Meves A., Beyerle A., Pittelkow M. R. UVB-induced epidermal growth factor receptor phosphorylation is critical for downstream signaling and keratinocyte survival. Photochem Photobiol. 2000 Jul;72(1):135–140. doi: 10.1562/0031-8655(2000)072<0135:uiegfr>2.0.co;2. [DOI] [PubMed] [Google Scholar]
  100. Piccinni M. P., Beloni L., Livi C., Maggi E., Scarselli G., Romagnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med. 1998 Sep;4(9):1020–1024. doi: 10.1038/2006. [DOI] [PubMed] [Google Scholar]
  101. Prince M. M., Hildreth N. G. The influence of potential biases on the risk of breast tumors among women who received radiotherapy for acute postpartum mastitis. J Chronic Dis. 1986;39(7):553–560. doi: 10.1016/0021-9681(86)90200-6. [DOI] [PubMed] [Google Scholar]
  102. Raza A. Consilience across evolving dysplasias affecting myeloid, cervical, esophageal, gastric and liver cells: common themes and emerging patterns. Leuk Res. 2000 Jan;24(1):63–72. doi: 10.1016/s0145-2126(99)00152-6. [DOI] [PubMed] [Google Scholar]
  103. Raziuddin S., Shetty S., Ibrahim A. T-cell abnormality and defective interleukin-2 production in patients with carcinoma of the urinary bladder with schistosomiasis. J Clin Immunol. 1991 Mar;11(2):103–113. doi: 10.1007/BF00917746. [DOI] [PubMed] [Google Scholar]
  104. Richards J. S., Fitzpatrick S. L., Clemens J. W., Morris J. K., Alliston T., Sirois J. Ovarian cell differentiation: a cascade of multiple hormones, cellular signals, and regulated genes. Recent Prog Horm Res. 1995;50:223–254. doi: 10.1016/b978-0-12-571150-0.50014-7. [DOI] [PubMed] [Google Scholar]
  105. Rook G. A., Hernandez-Pando R., Lightman S. L. Hormones, peripherally activated prohormones and regulation of the Th1/Th2 balance. Immunol Today. 1994 Jul;15(7):301–303. doi: 10.1016/0167-5699(94)90075-2. [DOI] [PubMed] [Google Scholar]
  106. Saareks V., Mucha I., Sievi E., Vapaatalo H., Riutta A. Nicotine stereoisomers and cotinine stimulate prostaglandin E2 but inhibit thromboxane B2 and leukotriene E4 synthesis in whole blood. Eur J Pharmacol. 1998 Jul 17;353(1):87–92. doi: 10.1016/s0014-2999(98)00384-7. [DOI] [PubMed] [Google Scholar]
  107. Sawaoka H., Kawano S., Tsuji S., Tsuji M., Sun W., Gunawan E. S., Hori M. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa. Prostaglandins Leukot Essent Fatty Acids. 1998 Nov;59(5):313–316. doi: 10.1016/s0952-3278(98)90079-5. [DOI] [PubMed] [Google Scholar]
  108. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Gunawan E. S., Takei Y., Nagano K., Hori M. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol. 1998 Jun;274(6 Pt 1):G1061–G1067. doi: 10.1152/ajpgi.1998.274.6.G1061. [DOI] [PubMed] [Google Scholar]
  109. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Murata H., Hori M. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development. J Clin Gastroenterol. 1998;27 (Suppl 1):S47–S52. doi: 10.1097/00004836-199800001-00009. [DOI] [PubMed] [Google Scholar]
  110. Sawaoka H., Tsuji S., Tsujii M., Gunawan E. S., Sasaki Y., Kawano S., Hori M. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest. 1999 Dec;79(12):1469–1477. [PubMed] [Google Scholar]
  111. Schreinemachers D. M., Everson R. B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994 Mar;5(2):138–146. doi: 10.1097/00001648-199403000-00003. [DOI] [PubMed] [Google Scholar]
  112. Schrör K., Zimmermann K. C., Tannhäuser R. Augmented myocardial ischaemia by nicotine--mechanisms and their possible significance. Br J Pharmacol. 1998 Sep;125(1):79–86. doi: 10.1038/sj.bjp.0702061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Schäffer M., Barbul A. Lymphocyte function in wound healing and following injury. Br J Surg. 1998 Apr;85(4):444–460. doi: 10.1046/j.1365-2168.1998.00734.x. [DOI] [PubMed] [Google Scholar]
  114. Scott M., Stites D. P., Moscicki A. B. Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol. 1999 Sep;6(5):751–755. doi: 10.1128/cdli.6.5.751-755.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Singer A. J., Clark R. A. Cutaneous wound healing. N Engl J Med. 1999 Sep 2;341(10):738–746. doi: 10.1056/NEJM199909023411006. [DOI] [PubMed] [Google Scholar]
  116. Spitz M. R., Wei Q., Li G., Wu X. Genetic susceptibility to tobacco carcinogenesis. Cancer Invest. 1999;17(8):645–659. doi: 10.3109/07357909909032849. [DOI] [PubMed] [Google Scholar]
  117. Spivak MYa, Lakatosh V. P., Lazarenko L. M., Lyanenko L. M., Azarskova M. V., Mikhailenko O. M., Tkáciková L., Boroda A. M. Interrelation of lymphocyte subpopulations in peripheral blood under cervical papillomavirus infection. Folia Microbiol (Praha) 1999;44(6):721–725. doi: 10.1007/BF02825669. [DOI] [PubMed] [Google Scholar]
  118. Strand S., Galle P. R. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today. 1998 Feb;4(2):63–68. doi: 10.1016/S1357-4310(97)01191-X. [DOI] [PubMed] [Google Scholar]
  119. Subbaramaiah K., Zakim D., Weksler B. B., Dannenberg A. J. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc Soc Exp Biol Med. 1997 Nov;216(2):201–210. doi: 10.3181/00379727-216-44170. [DOI] [PubMed] [Google Scholar]
  120. Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol. 2000 Oct;53(5):255–261. doi: 10.1136/mp.53.5.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Takahashi Y., Kawahara F., Noguchi M., Miwa K., Sato H., Seiki M., Inoue H., Tanabe T., Yoshimoto T. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2. FEBS Lett. 1999 Oct 22;460(1):145–148. doi: 10.1016/s0014-5793(99)01328-9. [DOI] [PubMed] [Google Scholar]
  122. Taketo M. M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst. 1998 Nov 4;90(21):1609–1620. doi: 10.1093/jnci/90.21.1609. [DOI] [PubMed] [Google Scholar]
  123. Thanos D., Maniatis T. NF-kappa B: a lesson in family values. Cell. 1995 Feb 24;80(4):529–532. doi: 10.1016/0092-8674(95)90506-5. [DOI] [PubMed] [Google Scholar]
  124. Thun M. J., Namboodiri M. M., Heath C. W., Jr Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991 Dec 5;325(23):1593–1596. doi: 10.1056/NEJM199112053252301. [DOI] [PubMed] [Google Scholar]
  125. Tomozawa S., Nagawa H., Tsuno N., Hatano K., Osada T., Kitayama J., Sunami E., Nita M. E., Ishihara S., Yano H. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer. 1999 Dec;81(8):1274–1279. doi: 10.1038/sj.bjc.6694262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  126. Tsuji S., Kawano S., Sawaoka H., Takei Y., Kobayashi I., Nagano K., Fusamoto H., Kamada T. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines. Prostaglandins Leukot Essent Fatty Acids. 1996 Sep;55(3):179–183. doi: 10.1016/s0952-3278(96)90095-2. [DOI] [PubMed] [Google Scholar]
  127. Tsujii M., DuBois R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995 Nov 3;83(3):493–501. doi: 10.1016/0092-8674(95)90127-2. [DOI] [PubMed] [Google Scholar]
  128. Tsujii M., Kawano S., DuBois R. N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3336–3340. doi: 10.1073/pnas.94.7.3336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998 May 29;93(5):705–716. doi: 10.1016/s0092-8674(00)81433-6. [DOI] [PubMed] [Google Scholar]
  130. Ung A., Kramer T. R., Schiffman M., Herrero R., Bratti M. C., Burk R. D., Swanson C. A., Sherman M. E., Hutchinson M. L., Alfaro M. Soluble interleukin 2 receptor levels and cervical neoplasia: results from a population-based case-control study in Costa Rica. Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):249–253. [PubMed] [Google Scholar]
  131. Vaganova I. G. Apoptoz i proliferatsiia épiteliotsitov éktotserviksa u bol'nykh papillomavirusnym i khlamidiinym tservitsitom. Vopr Onkol. 2000;46(5):578–582. [PubMed] [Google Scholar]
  132. Vainio H., Morgan G. Cyclo-oxygenase 2 and breast cancer prevention. Non-steroidal anti-inflammatory agents are worth testing in breast cancer. BMJ. 1998 Sep 26;317(7162):828–828. doi: 10.1136/bmj.317.7162.828. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Vane J. R., Bakhle Y. S., Botting R. M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120. doi: 10.1146/annurev.pharmtox.38.1.97. [DOI] [PubMed] [Google Scholar]
  134. Vogelstein B., Fearon E. R., Hamilton S. R., Kern S. E., Preisinger A. C., Leppert M., Nakamura Y., White R., Smits A. M., Bos J. L. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988 Sep 1;319(9):525–532. doi: 10.1056/NEJM198809013190901. [DOI] [PubMed] [Google Scholar]
  135. Wallenius V., Wallenius K., Jansson J. O. Normal pharmacologically-induced, but decreased regenerative liver growth in interleukin-6-deficient (IL-6(-/-)) mice. J Hepatol. 2000 Dec;33(6):967–974. doi: 10.1016/s0168-8278(00)80130-0. [DOI] [PubMed] [Google Scholar]
  136. Wang L. S., Chow K. C., Wu Y. C., Li W. Y., Huang M. H. Detection of Epstein-Barr virus in esophageal squamous cell carcinoma in Taiwan. Am J Gastroenterol. 1999 Oct;94(10):2834–2839. doi: 10.1111/j.1572-0241.1999.01425.x. [DOI] [PubMed] [Google Scholar]
  137. Watanabe M., McCormick K. L., Volker K., Ortaldo J. R., Wigginton J. M., Brunda M. J., Wiltrout R. H., Fogler W. E. Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis. Am J Pathol. 1997 May;150(5):1869–1880. [PMC free article] [PubMed] [Google Scholar]
  138. Westby M., Marriott J. B., Guckian M., Cookson S., Hay P., Dalgleish A. G. Abnormal intracellular IL-2 and interferon-gamma (IFN-gamma) production as HIV-1-assocated markers of immune dysfunction. Clin Exp Immunol. 1998 Feb;111(2):257–263. doi: 10.1046/j.1365-2249.1998.00505.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Whitby D., Boshoff C. Kaposi's sarcoma herpesvirus as a new paradigm for virus-induced oncogenesis. Curr Opin Oncol. 1998 Sep;10(5):405–412. doi: 10.1097/00001622-199809000-00007. [DOI] [PubMed] [Google Scholar]
  140. White C. D., Macatol F. R., DeJosef A. B. Inflammatory cell infiltrate in the cervix as a predictor of residual cervical intraepithelial neoplasia after conization. J Reprod Med. 1992 Sep;37(9):799–802. [PubMed] [Google Scholar]
  141. Williams M. P., Pounder R. E. Helicobacter pylori: from the benign to the malignant. Am J Gastroenterol. 1999 Nov;94(11 Suppl):S11–S16. doi: 10.1016/s0002-9270(99)00657-7. [DOI] [PubMed] [Google Scholar]
  142. Wolff H., Saukkonen K., Anttila S., Karjalainen A., Vainio H., Ristimäki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998 Nov 15;58(22):4997–5001. [PubMed] [Google Scholar]
  143. Xu Z. G., Iwatsuki K., Oyama N., Ohtsuka M., Satoh M., Kikuchi S., Akiba H., Kaneko F. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. Br J Cancer. 2001 Apr 6;84(7):920–925. doi: 10.1054/bjoc.2000.1687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Yamamoto T., Nakamura Y., Kishimoto K., Takeuchi H., Shirakata M., Mitsuya T., Hirai K. Epstein-Barr virus (EBV)-infected cells were frequently but dispersely detected in T-cell lymphomas of various types by in situ hybridization with an RNA probe specific to EBV-specific nuclear antigen 1. Virus Res. 1999 Dec 1;65(1):43–55. doi: 10.1016/s0168-1702(99)00101-x. [DOI] [PubMed] [Google Scholar]
  145. Yang T., Schnermann J. B., Briggs J. P. Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro. Am J Physiol. 1999 Jul;277(1 Pt 2):F1–F9. doi: 10.1152/ajprenal.1999.277.1.F1. [DOI] [PubMed] [Google Scholar]
  146. Yao R., Rioux N., Castonguay A., You M. Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res. 2000 Dec;26(8):731–742. doi: 10.1080/01902140150216783. [DOI] [PubMed] [Google Scholar]
  147. Yeung M. C., Lau A. S. Tumor suppressor p53 as a component of the tumor necrosis factor-induced, protein kinase PKR-mediated apoptotic pathway in human promonocytic U937 cells. J Biol Chem. 1998 Sep 25;273(39):25198–25202. doi: 10.1074/jbc.273.39.25198. [DOI] [PubMed] [Google Scholar]
  148. Yucel-Lindberg T., Ahola H., Carlstedt-Duke J., Modéer T. Involvement of tyrosine kinases on cyclooxygenase expression and prostaglandin E2 production in human gingival fibroblasts stimulated with interleukin-1beta and epidermal growth factor. Biochem Biophys Res Commun. 1999 Apr 13;257(2):528–532. doi: 10.1006/bbrc.1999.0523. [DOI] [PubMed] [Google Scholar]
  149. Zhou B. P., Hu M. C., Miller S. A., Yu Z., Xia W., Lin S. Y., Hung M. C. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem. 2000 Mar 17;275(11):8027–8031. doi: 10.1074/jbc.275.11.8027. [DOI] [PubMed] [Google Scholar]
  150. al-Saleh W., Giannini S. L., Jacobs N., Moutschen M., Doyen J., Boniver J., Delvenne P. Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix. J Pathol. 1998 Mar;184(3):283–290. doi: 10.1002/(SICI)1096-9896(199803)184:3<283::AID-PATH25>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  151. del Peso L., González-García M., Page C., Herrera R., Nuñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997 Oct 24;278(5338):687–689. doi: 10.1126/science.278.5338.687. [DOI] [PubMed] [Google Scholar]
  152. zur Hausen A., Brink A. A., Craanen M. E., Middeldorp J. M., Meijer C. J., van den Brule A. J. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res. 2000 May 15;60(10):2745–2748. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES